

In the Claims

Please amend the specification as follows.

1. (Currently Amended) An isolated and purified peptide of a ~~chemokine~~, a variant, or a derivative thereof, comprising no more than 30 amino acid residues, wherein the peptide comprises residues X₁-Asp-Pro-X₂-X₃-X₄-Trp-X₅-Gln or consists of X₂-X₃-X₄ or Trp-X₅-Gln, wherein X₁ is Ala, Ile or Leu, X₂ is Lys, Ser or Thr, X₄ is Lys, Glu, Ser or Arg, X₅ is Val or Ile, and X₃ is any amino acid, and wherein the peptide inhibits the activity of at least one native chemokine.
2. (Cancelled)
3. (Previously Presented) The peptide of claim 1 which is not a peptide of interleukin-8 (IL-8) or neutrophil activating protein-2 (NAP-2).
4. (Previously Presented) The peptide of claim 1 which is a variant of a peptide of monocyte chemotactic protein-1 (MCP-1).
5. (Cancelled)
6. (Previously Presented) The peptide of claim 1 which is a peptide of a CC chemokine.
7. (Previously Presented) The peptide of claim 6 wherein the CC chemokine is MCP-1, regulated on activation, normal T expressed and secreted protein (RANTES), monocyte chemotactic protein-2 (MCP-2), monocyte chemotactic protein-3 (MCP-3), monocyte chemotactic protein-4 (MCP-4), eotaxin, macrophage inflammatory protein-1 α (MIP1 α), MIP1 β , liver and activation regulated chemokine (LARC), I309, hemofiltrate CC-chemokine -1 (HCC-1), thymus and activation regulated chemokine (TARC) or chemokine beta 8 (Ck β 8).

8. (Previously Presented) The peptide of claim 1 which is a peptide of a CXC chemokine.
9. (Previously Presented) The peptide of claim 8 wherein the CXC chemokine is interferon inducible protein 10 (IP-10), platelet factor-4 (PF-4), stromal cell-derived factor-1 (SDF-1 α), NAP-2, growth regulated oncogene alpha (GRO α), GRO β , GRO γ or epithelial neutrophil activating peptide-78 (ENA78).
10. (Previously Presented) The peptide of claim 8 wherein the CXC chemokine is IL-8.
11. (Previously Presented) A cyclic reverse sequence derivative (CRD) of a peptide of a chemokine or a variant thereof.
- 12-41. (Cancelled)
42. (Previously Presented) The peptide of claim 4 which is Cys-Leu-Asp-Pro-Lys-Gln-Lys-Trp-Ile-Gln (SEQ ID NO:85).
43. (Previously Presented) The derivative of claim 11 which is CRD-Cys-Leu-Asp-Pro-Lys-Gln-Lys-Trp-Ile-Gln-Cys.